POPULARITY
Categories
A team of researchers from the Te Whai Ao Dodd-Walls Centre have developed a potential gamechanger in the detection and diagnosis of prostate cancer.
In this episode, we dive deep into the evolving landscape of prostate cancer screening, diagnosis, and treatment. Our guests— Richard Pullen, EdD, RN and Virginia Holter, DNP, APRN, FNP-BC—join us to clear up the confusion around PSA testing, the role of digital rectal exams, and how new imaging technologies are changing the way we detect prostate cancer. We explore the risk factors that matter most, from age and race to genetic mutations such as BRCA1 and 2, obesity, and even environmental exposures. You'll also hear about the complex decisions patients and physicians face together—from whether or not to get screened, to navigating treatment options such as active surveillance, prostatectomy, or high-intensity focused ultrasound ablation. Importantly, we tackle some often-overlooked topics, including impacts on sexual function and prostate cancer in transgender women. If you're over 40, have a loved one at risk, or just want to understand the science and policy behind one of the most common cancers in men—this episode is a must-listen.
What is the role of PSA for early detection, and how does hormone therapy affect cancer patients? These are questions we dig into in this episode. https://bit.ly/4lC0ZUdIn This Episode:01:32 - Road Trip-South Carolina & Shout Halellujah Potato Salad02:38 - Fighting For Your Life Is Boring - Andrew Reynolds04:44 - Prostate Cancer - Risks and Treatment09:46 - Why Was Biden's Prostate Cancer Detected So Late?14:52 - Signs and Symptoms of Prostate Cancer16:08 - Gleason Scoring for Prostate Cancer Grade19:18 - Hormone Therapy - Androgen Deprivation33:27 - Prostate Cancer and Partners36:21 - OutroAbout 1 in 8 men will be diagnosed with prostate cancer during their lifetime. Prostate cancer is the second-leading cause of cancer death in American men, behind lung cancer. Learn signs and symptoms, the role of PSA (prostate-specific antigen) for early detection and monitoring, how androgen-blocking therapy works, and how it affects patients and their partners.Support the showGet show notes and resources at our website: every1dies.org. Facebook | Instagram | YouTube | mail@every1dies.org
In today's episode, supported by Bayer, we had the pleasure of speaking with Alicia Morgans, MD, MPH, and Neal Shore, MD, FACS, about the FDA approval of darolutamide (Nubeqa) plus androgen deprivation therapy for patients with metastatic castration-sensitive prostate cancer (mCSPC). Morgans is the medical director of the survivorship program at Dana-Farber Cancer Institute; as well as an associate professor of medicine at Harvard Medical School, both in Boston, Massachusetts. Shore is the medical director of the Carolina Urologic Research Center. In our exclusive interview, Drs Morgans and Shore discussed the significance of this approval; key efficacy, safety, and quality of life data from the pivotal phase 3 ARANOTE trial (NCT04736199); and how this regulatory decision both opens doors for the treatment of more patients and raises questions about the optimal role of darolutamide in the management of mCSPC.
We often panic at the word cancer. For men diagnosed with prostate cancer, it can feel like a threat to their very identity. Many fear it signals the end of their masculinity. But what if there's a better, bolder way to approach treatment? Stephen Petteruti, DO, empowers his patients to “fight prostate cancer like a […]
H&P Disability Direct - Live Answers on the Road to VA Compensation
Here is the link to the Williams Waiver https://www.hillandponton.com/wp-content/uploads/2025/05/Waiver-example.pdfVA Disability Calculator is here https://www.hillandponton.com/va-disability-calculator/Struggling to get the benefits you know you deserve? Get a free case evaluation now! - https://www.hillandponton.com/free-case-evaluation?utm_source=youtube&utm_medium=organic-video&utm_campaign=description&utm_id=Livestream+ShowJoin in our Live VA Disability Q&A Session in which we answer your questions live. We can't get to every single question so we will answer them as they come in. If you have any questions about the VA Disability Benefits process you can ask the question in the comment section when we go live and a little earlier. We are nationwide VA Accredited Disability Lawyers. We can't wait to answer your questions!For a FREE Case Evaluation go here: https://www.hillandponton.com/free-ca...Visit our website at https://www.hillandponton.com/?utm_so...Like us on Facebook at www.facebook.com/HillandPontonFor questions please email us at Info@hillandponton.comSpeakers: Attorney Matthew HillThe content of this YouTube channel is provided for informational purposes only and is not intended to constitute legal advice. You should not rely upon any information contained on this YouTube channel for legal advice. Viewing this YouTube channel is not intended to and shall not create an attorney-client relationship between you and Hill and Ponton, PA. Messages or other forms of communication that you transmit to this YouTube channel will not create an attorney-client relationship and thus information contained in such communications may not be protected as privileged. Hill and Ponton, PA does not make any representation, warranty, or guarantee about the accuracy of the information contained in this YouTube channel or in links to other YouTube channels or websites. This YouTube channel is provided "as is," does not represent that any outcome or result from the viewing of this channel. Your use viewing of this YouTube channel is at your own risk. You enjoy this YouTube channel and its contents only for personal, non-commercial purposes. Neither Hill and Ponton, PA, nor anyone acting on their behalf, will be liable under any circumstances for damages of any kind.
Genetic factors play a critical role in prostate cancer treatment planning, with both germline and somatic mutations guiding therapeutic decisions. The Association of Cancer Care Centers (ACCC) remains committed to improving prostate cancer care and has developed the Metastatic Prostate Cancer Handbook: A Guide to Optimizing Outcomes with Germline and Somatic Testing. In this episode, CANCER BUZZ speaks with Andrea Murphy, FNP-C, ACGN, CGRA, genetics nurse practitioner at Mary Bird Perkins Cancer Center and Amy D. Smith, FNP-BC, director at Meredith & Jeannie Ray Cancer Center, about the impact this handbook has had on patient care delivery, measuring success during the pilot program, and recommendations for sustaining germline and somatic mutation testing in clinical practice. “I think a lot of people were surprised, definitely with germline testing, that all metastatic patients met the criteria [for testing]…”– Andrea (Ani) Murphy, FNP-C, ACGN, CGRA “The other thing that the [hand]book did is [give] us a good outline on what our deficiencies were, where we wanted to go with testing...and just pretty much set it up so that it was easy for us to follow.” – Amy D. Smith, NP-BC “Overall, I think the handbook could give anybody the guidance that they need to set up their own program.” – Amy D. Smith, NP-BC Andrea (Ani) Murphy, FNP-C, ACGN, CGRA Nurse Practitioner – Genetics Mary Bird Perkins Cancer Center Baton Rouge, LA Amy D. Smith, FNP-BC Director Meredith & Jeannie Ray Cancer Center Ivinson Memorial Hospital Laramie, Wyoming Resources: ACCC Metastatic Prostate Cancer Handbook: A Guide to Optimizing Outcomes with Germline and Somatic Testing Understanding the Uptake and Challenges of Genetic Testing Guidelines for Prostate Cancer NCCN Guidelines and Frameworks for Prostate Cancer ACCC Prostate Cancer Resources
Does a high PSA automatically mean you need a biopsy? Think again.In this eye-opening episode, Dr. Stephen Petteruti challenges outdated prostate care protocols and reveals the critical questions every man should ask before making any big decisions.Learn how cutting-edge tools like MRIs and biomarker tracking can often replace invasive biopsies, offering a safer, smarter way to monitor your health. Plus, Dr. Stephen dives into the financial conflicts of interest that might be influencing your care and introduces powerful tests like the calcium score and PSMA PET scan to help you see the bigger picture of your long-term health.Listen now and walk into your next doctor's visit armed with the right questions. Prostate Cancer Alert: What to Ask Your Doctor When Your PSA Is High.Enjoy the podcast? Subscribe and leave a 5-star review!Dr. Stephen Petteruti is a leading Functional Medicine Physician dedicated to enhancing vitality by addressing health at a cellular level. Combining the best of conventional medicine with advancements in cellular biology, he offers a patient-centered approach through his practice, Intellectual Medicine 120. A seasoned speaker and educator, he has lectured at prestigious conferences like A4M and ACAM, sharing his expertise on anti-aging. His innovative methods include concierge medicine and non-invasive anti-aging treatments, empowering patients to live longer, healthier lives.Website: www.intellectualmedicine.com Website: https://www.theprostateprotocol.com/ YouTube: https://www.youtube.com/@intellectualmedicine LinkedIn: https://www.linkedin.com/in/drstephenpetteruti/ Instagram: instagram.com/intellectualmedine Consultation: https://www.theprostateprotocol.com/book-a-consultation Store: https://www.theprostateprotocol.com/store Community: https://www.theprostateprotocol.com/products/communities/v2/fightcancerlikeaman/home Disclaimer: The content presented in this video reflects the opinions and clinical experience of Dr. Stephen Petteruti and is intended for informational and educational purposes only. It is not medical advice and should not be used as a substitute for professional diagnosis, treatment, or guidance from your personal healthcare provider. Always consult your physician or qualified healthcare professional before making any changes to your health regimen or treatment plan.Produced by https://www.BroadcastYourAuthority.com#ProstateCancer #Biopsy #MensHealth
In this series, the host Catherine Glass welcomes Stacy Loeb, a renowned urologist and lifestyle medicine advocate, to explore the growing impact of environmental factors on men's health. From the risks of microplastics and the benefits of plant-based diets to the carbon cost of prostate procedures, these conversations challenge conventional clinical perspectives and offer practical, planet-conscious solutions for modern urology.
Today we're talking about prostate cancer prevention….Now before your eyes glaze over or you assume this is just for someone older or someone else, let me assure you: this is something every man over 40 should know — and every man under 40 should be aware of so you can build resilient habits.Because- The good news? You have more control than you might think.Prostate cancer affects 1 in 8 men in the United States. Much the same as the risk women have for breast cancer. But while some factors like age and genetics can't be changed, many of the biggest risks for prostate cancer are lifestyle-related. And the genetics can be turned off.So today, I'm giving you 6 natural, science-backed, and do-able strategies that can help reduce your risk and improve your overall health.These aren't gimmicks. These are things I teach in my practice. And these strategies will support not just your prostate, but your energy, mood, metabolism, and long-term vitality
Today on the Dr. Geo Prostate Podcast, Dr. Geo sits down with Dr. Jacob Meyers, Director of Research and Development at LynxDx, and a scientist with a fascinating background spanning malaria research and genetic testing. Together, they unpack the science behind MyProstateScore 2.0 (MPS2) — a new urine-based test designed to help men and their doctors make smarter, more precise decisions about prostate cancer screening and whether a biopsy is truly needed.In this insightful conversation, you'll learn:The story behind MPS2 and how it moves beyond PSA aloneWhy the test focuses on detecting more aggressive prostate cancerThe unique biomarkers (including TMPRSS2:ERG fusion and KLK3) that set MPS2 apartHow MPS2 can help avoid unnecessary biopsies and even be done at home — no prostate massage requiredFuture directions in biomarker development and what's next for prostate cancer diagnosticsThis episode is full of practical, empowering information for men looking to take control of their prostate health and for clinicians seeking to stay on the cutting edge.
Dr. Neeraj Agarwal and Dr. Jeanny Aragon-Ching discuss important advances in the treatment of prostate, bladder, and kidney cancers that were presented at the 2025 ASCO Annual Meeting. TRANSCRIPT Dr. Neeraj Agarwal: Hello, and welcome to the ASCO Daily News Podcast. I am Dr. Neeraj Agarwal, your guest host of the ASCO Daily News Podcast today. I am the director of the Genitourinary Oncology Program and a professor of medicine at the University of Utah Huntsman Cancer Institute and editor-in-chief of the ASCO Daily News. I am delighted to be joined by Dr. Jeanny Aragon-Ching, a GU medical oncologist and the clinical program director of the GU Center at the Inova Schar Cancer Institute in Virginia. Today, we will be discussing some key abstracts in GU oncology that were presented at the 2025 ASCO Annual Meeting. Our full disclosures are available in the transcript of this episode. Jeanny, it is great to have you on the podcast. Dr. Jeanny Aragon-Ching: Oh, thank you so much, Neeraj. Dr. Neeraj Agarwal: Jeanny, let's begin with some prostate cancer abstracts. Let's begin with Abstract 5017 titled, “Phase 1 study results of JNJ-78278343 (pasritamig) in metastatic castration-resistant prostate cancer.” Can you walk us through the design and the key findings of this first-in-human trial? Dr. Jeanny Aragon-Ching: Yeah, absolutely, Neeraj. So this study, presented by Dr. Capucine Baldini, introduces pasritamig, a first-in-class T-cell redirecting bispecific antibody that simultaneously binds KLK2 on prostate cancer cells and CD3 receptor complexes on T cells. KLK2 is also known as human kallikrein 2, which is selectively expressed in prostate tissue. And for reference, KLK3 is what we now know as the PSA, prostate-specific antigen, therefore making it an attractive and specific target for therapeutic engagement. Now, while this was an early, first-in-human, phase 1 study, it enrolled 174 heavily pretreated metastatic CRPC patients. So many were previously treated with ARPIs, taxanes, and radioligand therapy. So given the phase 1 nature of this study, the primary objective was to determine the safety and the RP2D, which is the recommended phase 2 dose. Secondary objectives included preliminary assessment of antitumor activity. So, pasritamig was generally well tolerated. There were no treatment-related deaths. Serious adverse events were rare. And in the RP2D safety cohort, where patients received the step-up dosing up to 300 mg of IV every 6 weeks, the most common treatment-related adverse events were low-grade infusion reactions. There was fatigue and grade 1 cytokine release syndrome, what we call CRS. And no cases of neurotoxicity, or what we call ICANS, the immune effector cell-associated neurotoxicity syndrome, reported. Importantly, the CRS occurred in just about 8.9% of patients. All were grade 1. No patients required tocilizumab or discontinued treatment due to adverse events. So, this suggests a favorable safety profile, allowing hopefully for outpatient administration without hospitalization, which will be very important when we're thinking about bispecifics moving forward. In terms of efficacy, pasritamig showed promising activity. About 42.4% of evaluable patients achieved a PSA50 response. Radiographic PFS was about 6.8 months. And among patients with measurable disease, the objective response rate was about 16.1% in those with lymph node or bone metastases, and about 3.7% in those with visceral disease, with a median duration of response of about 11.3 months. So, altogether, this data suggests that pasritamig may offer a well-tolerated and active new potential option for patients with metastatic CRPC. Again, as a reminder, with the caveat that this is still an early phase 1 study. Dr. Neeraj Agarwal: Thank you, Jeanny. These are promising results for a bispecific T-cell engager, pasritamig, in prostate cancer. I agree, the safety and durability observed here stand out, and this opens the door for further development, possibly even in earlier disease settings. So, shifting now from immunotherapy to the evolving role of genomics in prostate cancer. So let's discuss Abstract 5094, a real-world, retrospective analysis exploring the prognostic impact of homologous recombination repair gene mutations, especially BRCA1 and BRCA2 mutations, in metastatic hormone-sensitive prostate cancer. Can you tell us more about this abstract, Jeanny? Dr. Jeanny Aragon-Ching: Sure, Neeraj. So this study was presented by Dr. David Olmos, represents one of the largest real-world analyses we have evaluating the impact of homologous recombination repair, or what we would call HRR, alterations in metastatic hormone-sensitive prostate cancer. So, this cohort included 556 men who underwent paired germline and somatic testing. Now, about 30% of patients had HRR alterations, with about 12% harboring BRCA1 or BRCA2 mutations and 16% having alterations in other HRR genes. Importantly, patients were stratified via CHAARTED disease volume, and outcomes were examined across treatment approaches, including ADT alone, doublet therapy, and triplet therapy. The prevalence of BRCA and HRR alterations were about similar between the metastatic hormone-sensitive prostate cancer and the metastatic castrate-resistant prostate cancer, with no differences observed, actually, between the patients with high volume versus low volume disease. So, the key finding was that BRCA and HRR alterations were associated with poor clinical outcomes in metastatic hormone-sensitive prostate cancer. And notably, the impact of these alterations may actually be even greater in metastatic hormone-sensitive prostate cancer than previously reported in metastatic CRPC. So, the data showed that when BRCA mutations are present, the impact of the volume of disease is actually limited. So, poor outcomes were observed across the board for both high-volume and low-volume groups. So, the analysis showed that patients with HRR alterations had significantly worse outcomes compared to patients without HRR alterations. Median radiographic progression-free survival was about 20.5 months for the HRR-altered patients versus 30.6 months for the non-HRR patients, with a hazard ratio of 1.6. Median overall survival was 39 months for HRR-altered patients compared to 55.7 months for the non-HRR patients, with a hazard ratio of 1.5. Similar significant differences were observed when BRCA-mutant patients were compared with patients harboring non-BRCA HRR mutations. Overall, poor outcomes were independent of treatment of ARPI or taxanes. Dr. Neeraj Agarwal: Thank you, Jeanny. So, these data reinforce homologous recombination repair mutations as both a predictive and prognostic biomarker, not only in the mCRPC, but also in the metastatic hormone-sensitive setting as well. It also makes a strong case for incorporating genomic testing early in the disease course and not waiting until our patients have castration-resistant disease. Dr. Jeanny Aragon-Ching: Absolutely, Neeraj. And I think this really brings home the point and the lead up to the AMPLITUDE trial, which is LBA5006, a phase 3 trial that builds on this very concept of testing with a PARP inhibitor, niraparib, in the hormone-sensitive space. Can you tell us a little bit more about this abstract, Neeraj? Dr. Neeraj Agarwal: Sure. So, the AMPLITUDE trial, a phase 3 trial presented by Dr. Gerhardt Attard, enrolled 696 patients with metastatic hormone-sensitive prostate cancer and HRR gene alterations. 56% of these patients had BRCA1 and BRCA2 mutations. Patients were randomized to receive abiraterone with or without niraparib, a PARP inhibitor. The majority of patients, 78% of these patients, had high-volume metastatic hormone-sensitive prostate cancer, and 87% of these patients had de novo metastatic HSPC. And 16% of these patients received prior docetaxel, which was allowed in the clinical trial. So, with a median follow-up of nearly 31 months, radiographic progression-free survival was significantly prolonged with the niraparib plus abiraterone combination, and median was not reached in this arm, compared to abiraterone alone, which was 29.5 months, with a hazard ratio of 0.63, translating to a 37% reduction in risk of progression or death. This benefit was even more pronounced in the BRCA1 and BRCA2 subgroup, with a 48% reduction in risk of progression, with a hazard ratio of 0.52. Time to symptomatic progression also improved significantly across all patients, including patients with BRCA1, BRCA2, and HRR mutations. Although overall survival data remain immature, early trends favored the niraparib plus abiraterone combination. The safety profile was consistent with prior PARP inhibitor studies, with grade 3 or higher anemia and hypertension were more common but manageable. Treatment discontinuation due to adverse events remained low at 11%, suggesting that timely dose modifications when our patients experience grade 3 side effects may allow our patients to continue treatment without discontinuation. These findings support niraparib plus abiraterone as a potential new standard of care in our patients with metastatic hormone-sensitive prostate cancer with HRR alterations, and especially in those who had BRCA1 and BRCA2 mutations. Dr. Jeanny Aragon-Ching: Thank you, Neeraj. This trial is especially exciting because it brings PARP inhibitors earlier into the treatment paradigm. Dr. Neeraj Agarwal: Exactly. And it is exciting to see the effect of PARP inhibitors in the earlier setting. So Jeanny, now let's switch gears a bit to bladder cancer, which also saw several impactful studies. Could you tell us about Abstract 4502, an exploratory analysis from the EV-302 trial, which led to approval of enfortumab vedotin plus pembrolizumab for our patients with newly diagnosed metastatic bladder cancer? So here, the authors looked at the outcomes in patients who achieved a confirmed complete response with EV plus pembrolizumab. Dr. Jeanny Aragon-Ching: Sure, Neeraj. So, EV-302 demonstrated significant improvements in progression-free and overall survival for patients previously treated locally advanced or metastatic urothelial cancer, I'll just call it metastatic UC, as a frontline strategy, establishing EV, which is enfortumab vedotin, plus pembro, with pembrolizumab as standard of care in this setting. So, this year at ASCO, Dr Shilpa Gupta presented this exploratory responder analysis from the phase 3 EV-302 trial. Among 886 randomized patients, about 30.4% of patients, this is about 133, in the EV+P arm, and 14.5% of the patients in the chemotherapy arm, achieved a confirmed complete response. They call it the CCR rates. So for patients who achieved this, median PFS was not reached with EV+P compared to 26.9 months with chemotherapy, with a hazard ratio of 0.36, translating to a 64% reduction in the risk of progression. Overall survival was also improved. So the median OS was not reached in either arm, but the hazard ratio favored the EV+P at 0.37, translating to a 63% reduction in the risk of death. The median duration of complete response was not reached with EV+P compared to 15.2 months with chemotherapy. And among those patients who had confirmed CRs at 24 months, 78% of patients with the EV+P arm remained progression-free, and around 95% of the patients were alive, compared to 54% of patients who were progression-free and 86% alive of the patients in the chemotherapy arm. Safety among responders were also consistent with prior reports. Grade 3 or higher treatment-related adverse events occurred in 62% of EV+P responders and 72% of chemotherapy responders. Most adverse events were managed with dose modifications, and importantly, no treatment-related deaths were reported among those who were able to achieve complete response. So these findings further reinforce EV and pembro as the preferred first-line therapy for metastatic urothelial carcinoma, offering a higher likelihood of deep, durable responses with a fairly manageable safety profile. Dr. Neeraj Agarwal: Thank you for the great summary, Jeanny. These findings underscore the depth and durability of responses achievable with this combination and also suggest that achieving a response may be a surrogate for long-term benefit in patients with metastatic urothelial carcinoma. So now, let's move to Abstract 4503, an exploratory ctDNA analysis from the NIAGARA trial, which evaluated perioperative durvalumab, an immune checkpoint inhibitor, in muscle-invasive bladder cancer. So what can you tell us about this abstract? Dr. Jeanny Aragon-Ching: Absolutely, Neeraj. So, in NIAGARA, presented by Dr. Tom Powles, the addition of perioperative durvalumab to neoadjuvant chemotherapy, gem/cis, significantly improved event-free survival, overall survival, and pathologic complete response in patients with cisplatin-eligible muscle-invasive bladder cancer. Recall that this led to the U.S. FDA approval of this treatment regimen on March 28, 2025. So, a planned exploratory analysis evaluated the ctDNA dynamics and their association with clinical outcomes, which was the one presented recently at ASCO. So, the study found that the incidence of finding ctDNA positivity in these patients was about 57%. Following neoadjuvant treatment, this dropped to about 22%, with ctDNA clearance being more common in the durvalumab arm, about 41%, compared to the chemotherapy control arm of 31%. Notably, 97% of patients who remained ctDNA positive prior to surgery failed to achieve a pathologic CR. So, this indicates a strong association between ctDNA persistence and lack of tumor eradication. So, postoperatively, only about 9% of patients were ctDNA positive. So, importantly, durvalumab conferred an event-free survival benefit regardless of ctDNA status at both baseline and post-surgery. Among patients who were ctDNA positive at baseline, durvalumab led to a hazard ratio of 0.73 for EFS. So, this translates to a 27% reduction in the risk of disease recurrence, progression, or death compared to the control arm. In the post-surgical ctDNA-positive group, the disease-free survival was also improved with a hazard ratio of 0.49, translating to a 51% reduction in the risk of recurrence. So, these findings underscore the prognostic value of ctDNA and suggest that durvalumab provides clinical benefit irrespective of molecular residual disease status. So, the data also supports that ctDNA is a promising biomarker for future personalized strategies in the perioperative treatment of muscle-invasive bladder cancer. Dr. Neeraj Agarwal: Thank you, Jeanny. It is great to see that durvalumab is improving outcomes in these patients regardless of ctDNA status. However, based on these data, presence of ctDNA in our patients warrants a closer follow-up with imaging studies, because these patients with positive ctDNA seem to have a higher risk of recurrence. Dr. Jeanny Aragon-Ching: I agree, Neeraj. Let's round out the bladder cancer discussion with Abstract 4518, which reported the interim results of SURE-02, which is a phase 2 study evaluating neoadjuvant sacituzumab govitecan plus pembrolizumab in cisplatin-ineligible muscle-invasive bladder cancer. Can you tell us more about this abstract, Neeraj? Dr. Neeraj Agarwal: Sure, Jeanny. So, Dr Andrea Necchi presented interim results from the SURE-02 trial. This is a phase 2 study evaluating neoadjuvant sacituzumab govitecan plus pembrolizumab, followed by a response-adapted bladder-sparing treatment and adjuvant pembrolizumab in patients with muscle-invasive bladder cancer. So, in this interim analysis, 40 patients were treated and 31 patients were evaluable for efficacy. So, the clinical complete response rate was 38.7%. All patients achieving clinical complete response underwent bladder-sparing approach with a repeat TURBT instead of radical cystectomy. Additionally, 51.6% of patients achieved excellent pathologic response with a T stage of 1 or less after neoadjuvant therapy. The treatment was well tolerated, with only 12.9% of patients experiencing grade 3 or higher adverse events without needing dose reduction of sacituzumab. Molecular profiling, interestingly, showed that clinical complete response correlated with luminal and genomically unstable subtypes, while high stromal gene expression was associated with lack of response. These results suggest that sacituzumab plus pembrolizumab combination has promising activity in this setting, and tolerability, and along with other factors may potentially allow a bladder preservation approach in a substantial number of patients down the line. Dr. Jeanny Aragon-Ching: Yeah, agree with you, Neeraj. And the findings are very provocative and support completing the full trial enrollment and further exploration of this strategy in muscle-invasive bladder cancer in order to improve and provide further bladder-sparing strategies. Dr. Neeraj Agarwal: Agree. So, let's now turn to the kidney cancer, starting with Abstract 4505, the final overall analysis from CheckMate-214 trial, which evaluated nivolumab plus ipilimumab, so dual checkpoint inhibition strategy, versus sunitinib in our patients with metastatic clear cell renal cell carcinoma. Dr. Jeanny Aragon-Ching: Yeah, absolutely, Neeraj. So, the final 9-year analysis of the phase 3 CheckMate-214 trial confirms the long-term superiority of nivolumab and ipilimumab over sunitinib for first-line treatment of advanced metastatic renal cell carcinoma. So, this has a median follow-up of 9 years. Overall survival remains significantly improved with the combination. So, in the ITT patient population, the intention-to-treat, the hazard ratio for overall survival was 0.71. So, this translates to a 29% reduction in the risk of death. 31% of patients were alive at this 108-month follow-up compared to 20% only in those who got sunitinib. So, similar benefits were observed in the intermediate- and poor-risk groups with a hazard ratio of 0.69, and 30% versus 19% survival at 108 months. Importantly, a delayed benefit was also seen in those favorable-risk patients. So, the hazard ratio for overall survival improved from 1.45 in the initial report and now at 0.8 at 9 years follow-up, with 35% of patients alive at 108 months compared to 22% in those who got sunitinib. Progression-free survival also favored the nivo-ipi arm across all risk groups. At 96 months, the probability of remaining progression-free was about 23% compared to 9% in the sunitinib arm in the ITT patient population, 25% versus 9% in the intermediate- and poor-risk patients, and 13% compared to 11% in the favorable-risk patients. Importantly, at 96 months, 48% of patients in the nivo-ipi responders remained in response compared to just 19% in those who got sunitinib. And in the favorable-risk group, 36% of patients who responded remained in response, although data were not available for sunitinib in this subgroup. So, this data reinforces the use of nivolumab and ipilimumab as a durable and effective first-line effective strategy for standard of care across all risk groups for advanced renal cell carcinoma. Dr. Neeraj Agarwal: Thank you, Jeanny. And of course, since ipi-nivo data were presented, several other novel ICI-TKI combinations have emerged. And I'm really hoping to see very similar data with TKI-ICI combinations down the line. It is really important to note that we are not seeing any new safety signals with the ICI combinations or ICI-based therapies, which is very reassuring given the extended exposure. Dr. Jeanny Aragon-Ching: Absolutely agree with you there, Neeraj. Now, going on and moving on to Abstract 4514, which is the KEYNOTE-564 trial, and they reported on the 5-year outcomes of adjuvant pembrolizumab in clear cell RCC in patients who are at high risk for recurrence. Can you tell us a little bit more about this abstract, Neeraj? Dr. Neeraj Agarwal: Sure. So, the KEYNOTE-564 trial established pembrolizumab monotherapy as the first adjuvant regimen to significantly improve both disease-free survival and overall survival compared to placebo after surgery for patients with clear cell renal cell carcinoma. So, Dr Naomi Haas presented the 5-year update from this landmark trial. A total of 994 patients were randomized to receive either pembrolizumab or placebo. The median follow-up at the time of this analysis was approximately 70 months. Disease-free survival remained significantly improved with pembrolizumab. The median DFS was not reached with pembrolizumab compared to 68.3 months with placebo, with a hazard ratio of 0.71, translating to a 29% reduction in risk of recurrence. At 5 years, 60.9% of patients receiving pembrolizumab remained disease-free compared to 52.2% with placebo. Overall survival also favored pembrolizumab. The hazard ratio for OS was 0.66, translating to a 34% reduction in risk of death, with an estimated 5-year overall survival rate of 87.7% with pembrolizumab compared to 82.3% for placebo. Importantly, these benefits were consistent across all key subgroups, including patients with sarcomatoid features. In addition, no new serious treatment-related adverse events have been reported in the 3 years since treatment completion. So, these long-term data confirm pembrolizumab as a durable and effective standard adjuvant therapy for patients with resected, high-risk clear cell renal cell carcinoma. Dr. Jeanny Aragon-Ching: Thank you for that wonderful summary, Neeraj. Dr. Neeraj Agarwal: That wraps up our kidney cancer highlights. Any closing thoughts, Jeanny, before we conclude? Dr. Jeanny Aragon-Ching: It's been so wonderful reviewing these abstracts with you, Neeraj. So, the 2025 ASCO Annual Meeting showcased a lot of transformative data across GU cancers, from first-in-class bispecifics to long-term survival in RCC. And these findings are already shaping our clinical practices. Dr. Neeraj Agarwal: I agree. And we have covered a broad spectrum of innovations in GU cancers with strong clinical relevance. So, thank you, Jeanny, for joining me today and sharing your insights. And thank you to our listeners for joining us. You will find links to the abstracts discussed today in the transcript of this episode. If you find these conversations valuable, please take a moment to rate, review, and subscribe to the ASCO Daily News Podcast wherever you listen. Thank you so much. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Find out more about today's speakers: Dr. Neeraj Agarwal @neerajaiims Dr. Jeanny Aragon-Ching Follow ASCO on social media: @ASCO on Twitter ASCO on Bluesky ASCO on Facebook ASCO on LinkedIn Disclosures: Dr. Neeraj Agarwal: Consulting or Advisory Role: Pfizer, Bristol-Myers Squibb, AstraZeneca, Nektar, Lilly, Bayer, Pharmacyclics, Foundation Medicine, Astellas Pharma, Lilly, Exelixis, AstraZeneca, Pfizer, Merck, Novartis, Eisai, Seattle Genetics, EMD Serono, Janssen Oncology, AVEO, Calithera Biosciences, MEI Pharma, Genentech, Astellas Pharma, Foundation Medicine, and Gilead Sciences Research Funding (Institution): Bayer, Bristol-Myers Squibb, Takeda, Pfizer, Exelixis, Amgen, AstraZeneca, Calithera Biosciences, Celldex, Eisai, Genentech, Immunomedics, Janssen, Merck, Lilly, Nektar, ORIC Pharmaceuticals, Crispr Therapeutics, Arvinas Dr. Jeanny Aragon-Ching: Honoraria: Bristol-Myers Squibb, EMD Serono, Astellas Scientific and Medical Affairs Inc., Pfizer/EMD Serono Consulting or Advisory Role: Algeta/Bayer, Dendreon, AstraZeneca, Janssen Biotech, Sanofi, EMD Serono, MedImmune, Bayer, Merck, Seattle Genetics, Pfizer, Immunomedics, Amgen, AVEO, Pfizer/Myovant, Exelixis, Speakers' Bureau: Astellas Pharma, Janssen-Ortho, Bristol-Myers Squibb, Astellas/Seattle Genetics
UCSF's Dr. Rahul Aggarwal explains the role of clinical trials in advancing prostate cancer treatment and how trial design is evolving to match today's more personalized approaches. He highlights how UCSF has contributed to major prostate cancer therapies and emphasizes the importance of genetic and genomic testing in identifying suitable trials for each patient. Dr. Aggarwal explains the different trial phases, clarifies common myths—such as concerns about placebos—and stresses that trials are considered at every stage of disease. He also discusses efforts to improve access, affordability, and diversity in trial participation, including regional partnerships and digital matching tools. The talk encourages patients to be informed and proactive when considering clinical trials as part of their treatment plan. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 40800]
Dr Neeraj Agarwal from the University of Utah Huntsman Cancer Institute in Salt Lake City, Dr Andrew J Armstrong from Duke Cancer Institute in Durham, North Carolina, Dr Himisha Beltran from Dana-Farber Cancer Institute in Boston, Massachusetts, Dr Fred Saad from the University of Montreal Hospital Center in Québec, Canada, and Dr Rana R McKay from the UC San Diego Moores Cancer Center discuss recent updates on available and novel treatment strategies for prostate cancer. CME information and select publications here.
UCSF's Dr. Rahul Aggarwal explains the role of clinical trials in advancing prostate cancer treatment and how trial design is evolving to match today's more personalized approaches. He highlights how UCSF has contributed to major prostate cancer therapies and emphasizes the importance of genetic and genomic testing in identifying suitable trials for each patient. Dr. Aggarwal explains the different trial phases, clarifies common myths—such as concerns about placebos—and stresses that trials are considered at every stage of disease. He also discusses efforts to improve access, affordability, and diversity in trial participation, including regional partnerships and digital matching tools. The talk encourages patients to be informed and proactive when considering clinical trials as part of their treatment plan. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 40800]
UCSF's Dr. Rahul Aggarwal explains the role of clinical trials in advancing prostate cancer treatment and how trial design is evolving to match today's more personalized approaches. He highlights how UCSF has contributed to major prostate cancer therapies and emphasizes the importance of genetic and genomic testing in identifying suitable trials for each patient. Dr. Aggarwal explains the different trial phases, clarifies common myths—such as concerns about placebos—and stresses that trials are considered at every stage of disease. He also discusses efforts to improve access, affordability, and diversity in trial participation, including regional partnerships and digital matching tools. The talk encourages patients to be informed and proactive when considering clinical trials as part of their treatment plan. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 40800]
UCSF's Dr. Rahul Aggarwal explains the role of clinical trials in advancing prostate cancer treatment and how trial design is evolving to match today's more personalized approaches. He highlights how UCSF has contributed to major prostate cancer therapies and emphasizes the importance of genetic and genomic testing in identifying suitable trials for each patient. Dr. Aggarwal explains the different trial phases, clarifies common myths—such as concerns about placebos—and stresses that trials are considered at every stage of disease. He also discusses efforts to improve access, affordability, and diversity in trial participation, including regional partnerships and digital matching tools. The talk encourages patients to be informed and proactive when considering clinical trials as part of their treatment plan. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 40800]
The Cancer Pod: A Resource for Cancer Patients, Survivors, Caregivers & Everyone In Between.
Tell us your thoughts on this episode!In this episode of the Cancer Pod, Dr. Leah Sherman sits down with Dr. David Grew, a board-certified radiation oncologist and founder of Primr, a free digital video resource. They also go into details about prostate cancer, from early detection and PSA testing to the latest advancements in treatment options, including when active surveillance is possible vs. surgery and radiation therapy. Dr. Grew shares how Primr evolved from his inclination to use images to understand and explain medicine. His digitally crafted visual explanations are helping patients understand and navigate their diagnosis and treatment options. Tune in to learn about symptoms, high-risk factors, diagnostic tools like MRIs and genomic testing, and the importance of multiple medical opinions when managing prostate cancer.Click here for Dr. Grew's bio and all social media links to PrimrPrimr Website: https://www.primrmed.com/Direct link to Prostate Cancer Education on PrimrClinical Trial Explainers from Primer:The SABRE TrialThe INDICATE TrialThe CLARIFY TrialSupport the showOur website: https://www.thecancerpod.com Become a member of The Cancer Pod Community! Gain access to live events, exclusive content, and so much more. Join us today and be part of the journey!Email us: thecancerpod@gmail.com Follow @TheCancerPod on: Instagram Bluesky Facebook LinkedIn YouTube THANK YOU for listening!
Featuring perspectives from Dr Neeraj Agarwal, Dr Andrew J Armstrong, Dr Himisha Beltran, Dr Rana R McKay and Dr Fred Saad, moderated by Dr McKay, including the following topics: Introduction (0:00) Evolving Management of Nonmetastatic Hormone-Sensitive Prostate Cancer (HSPC) — Dr Saad (2:12) Current Treatment for Metastatic HSPC — Dr Armstrong (26:12) Role of PARP Inhibition in Metastatic Castration-Resistant Prostate Cancer (mCRPC) — Dr Agarwal (49:31) Current and Future Use of Radiopharmaceuticals for mCRPC — Dr McKay (1:12:51) Promising Novel Agents and Strategies Under Investigation for the Management of Prostate Cancer — Dr Beltran (1:36:11) CME information and select publications
Being told you have prostate cancer is a life-changing moment, but is doing nothing really the best option?In this episode, Dr. Stephen Petteruti questions the value of "watchful waiting" and "active surveillance," urging men to consider smarter, more proactive alternatives.Dr. Stephen explains why relying on repeated biopsies is not only risky but often unnecessary. He introduces non-biopsy monitoring—using MRIs, consistent biomarkers, and targeted lifestyle shifts like boosting vitamin D and lowering body fat—to track and influence health outcomes with less harm.If you want real options and honest insight, tune into the episode: Rethinking Prostate Cancer Care: Is Active Surveillance Enough?Enjoy the podcast? Subscribe and leave a 5-star review!Dr. Stephen Petteruti is a leading Functional Medicine Physician dedicated to enhancing vitality by addressing health at a cellular level. Combining the best of conventional medicine with advancements in cellular biology, he offers a patient-centered approach through his practice, Intellectual Medicine 120. A seasoned speaker and educator, he has lectured at prestigious conferences like A4M and ACAM, sharing his expertise on anti-aging. His innovative methods include concierge medicine and non-invasive anti-aging treatments, empowering patients to live longer, healthier lives.Website: www.intellectualmedicine.com Website: https://www.theprostateprotocol.com/ YouTube: https://www.youtube.com/@intellectualmedicine LinkedIn: https://www.linkedin.com/in/drstephenpetteruti/ Instagram: instagram.com/intellectualmedine Consultation: https://www.theprostateprotocol.com/book-a-consultation Store: https://www.theprostateprotocol.com/store Community: https://www.theprostateprotocol.com/products/communities/v2/fightcancerlikeaman/home Disclaimer: The content presented in this video reflects the opinions and clinical experience of Dr. Stephen Petteruti and is intended for informational and educational purposes only. It is not medical advice and should not be used as a substitute for professional diagnosis, treatment, or guidance from your personal healthcare provider. Always consult your physician or qualified healthcare professional before making any changes to your health regimen or treatment plan.
In this deeply personal episode of Guy Shrink, host Bill Roman sits down with his friend Matt Kutz, a professor at Florida International University, to discuss a life-altering diagnosis of advanced metastatic prostate cancer. Matt shares his journey from being an active, symptom-free athlete to facing a challenging reality that affects not only him but his family. With candid vulnerability, he opens up about the emotional and physical toll of treatments, the stigma surrounding prostate cancer, and the importance of routine checkups. Matt also introduces his initiative, Battle for the Bulge, aimed at raising awareness and supporting prostate cancer research. This episode is a powerful reminder to prioritize health, embrace a positive attitude, and lean on community in the face of adversity. Tune in for an inspiring conversation about resilience and hope. Connect with us across all platforms here: https://linktr.ee/guyshrink
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/TRR865. CME/MOC/AAPA credit will be available until June 30, 2026.Mission Possible in Prostate Cancer: Leveraging Genomics, Modern Therapeutics, and Individualized Patient Care In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and ZERO Prostate Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent medical education grants from AstraZeneca, Bayer HealthCare Pharmaceuticals Inc., and Johnson & Johnson.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/TRR865. CME/MOC/AAPA credit will be available until June 30, 2026.Mission Possible in Prostate Cancer: Leveraging Genomics, Modern Therapeutics, and Individualized Patient Care In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and ZERO Prostate Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent medical education grants from AstraZeneca, Bayer HealthCare Pharmaceuticals Inc., and Johnson & Johnson.Disclosure information is available at the beginning of the video presentation.
PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Video Podcast
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/TRR865. CME/MOC/AAPA credit will be available until June 30, 2026.Mission Possible in Prostate Cancer: Leveraging Genomics, Modern Therapeutics, and Individualized Patient Care In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and ZERO Prostate Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent medical education grants from AstraZeneca, Bayer HealthCare Pharmaceuticals Inc., and Johnson & Johnson.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/TRR865. CME/MOC/AAPA credit will be available until June 30, 2026.Mission Possible in Prostate Cancer: Leveraging Genomics, Modern Therapeutics, and Individualized Patient Care In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and ZERO Prostate Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent medical education grants from AstraZeneca, Bayer HealthCare Pharmaceuticals Inc., and Johnson & Johnson.Disclosure information is available at the beginning of the video presentation.
PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Audio Podcast
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/TRR865. CME/MOC/AAPA credit will be available until June 30, 2026.Mission Possible in Prostate Cancer: Leveraging Genomics, Modern Therapeutics, and Individualized Patient Care In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and ZERO Prostate Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent medical education grants from AstraZeneca, Bayer HealthCare Pharmaceuticals Inc., and Johnson & Johnson.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/TRR865. CME/MOC/AAPA credit will be available until June 30, 2026.Mission Possible in Prostate Cancer: Leveraging Genomics, Modern Therapeutics, and Individualized Patient Care In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and ZERO Prostate Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent medical education grants from AstraZeneca, Bayer HealthCare Pharmaceuticals Inc., and Johnson & Johnson.Disclosure information is available at the beginning of the video presentation.
In this episode of Idea Collider, host Mike Rea interviews Paul Peter Tak, CEO of Candel Therapeutics, discussing his remarkable journey from a clinician in Amsterdam to leading cutting-edge biotech companies. Paul shares pivotal moments in his career, the challenges of transitioning from academia to big pharma, and the innovative principles he applied. He dives deep into Candel's promising work in viral immunotherapies for cancers and the unique leadership and management philosophies that have guided his journey. Additionally, Paul Peter touches on his passion for leveraging collective intelligence and his unconventional hobbies that keep him grounded and creative. 00:00 Introduction and Guest Welcome00:59 Early Career and Passion for Medicine02:09 Transition to Industry and GSK Experience04:50 Building Successful Organizations07:42 Innovative Models in Pharma19:03 Joining Candel Therapeutics and Vision for the Future25:15 Transforming Cancer Treatment27:24 Challenges in Biotech Market28:45 Strategic Decisions and Prioritization31:39 Collaborations and External Partnerships33:07 Innovative Approaches and Future Prospects44:23 Leadership and Personal Insights Don't forget to Like, Share, Subscribe, Rate, and Review! Keep up with Paul Peter Tak;LinkedIn: https://www.linkedin.com/in/paul-peter-tak-md-phd-fmedsci-1b44749/ Follow Mike Rea On;Website: https://www.ideapharma.com/X: https://x.com/ideapharmaLinkedIn: https://www.linkedin.com/in/bigidea/ Listen to more fantastic podcast episodes: https://podcast.ideapharma.com/
In "Episode 7" of the series on "Present and future of diagnostics in prostate cancer", Dr. Marcin Miszczyk (PL) and Prof. Wolfgang Fendler (DE) discuss the role of PSMA-PET imaging in modern prostate cancer management.They examine how this advanced imaging modality compares to conventional techniques, and whether its improved sensitivity and specificity are enough to shift treatment paradigms. Drawing on key trials like proPSMA, ORIOLE, STORM, and RADIOSA, the episode highlights both the clinical value and the unresolved questions surrounding PSMA-PET, particularly regarding overdiagnosis, stage migration, and missed lesions.Dr. Miszczyk and Prof. Fendler consider its potential in dose escalation, personalised therapy, and integration with MRI for better staging. They also reflect on upcoming changes in clinical guidelines, especially for high-risk patients, and share a hopeful outlook on the impact of PSMA-PET in shaping more precise and effective prostate cancer care.For more EAU podcasts, please go to your favourite podcast app and subscribe to our podcast channel for regular updates: Apple Podcasts, Spotify, EAU YouTube channel.
This week, we present an inspiring episode for anyone interested in the history, present, and future of prostate cancer care. In this Legends in Urology installment of the BackTable Urology Podcast, Dr. Gerald Andriole joins guest host Dr. Niraj Badhiwala to reflect on a career that has left a lasting impact on the field. --- SYNPOSIS Dr. Andriole shares personal stories from his upbringing in Northeastern Pennsylvania and his journey into medicine. He reflects on his expedited education through Penn State and Jefferson Medical College and his path to urology. He discusses his pivotal work in prostate cancer screening, including the influence of major trials like The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial, and traces the evolution of surgical and diagnostic techniques. The conversation also touches on current innovations and the future of prostate cancer management, offering valuable advice for the next generation of urologists. --- TIMESTAMPS 00:00 - Introduction01:59 - From Childhood to Medical School06:48 - Discovering Urology16:52 - Pioneering Prostate Cancer Screening24:07 - The PLCO Study: Design and Challenges28:57 - Controversies and Criticisms in Prostate Cancer Screening33:29 - Evolving Practices in Prostate Cancer Management44:19 - Future of Prostate Cancer Treatment
Josh's Guests: Sylvie Beljanski - author, Winning the War on Cancer Use the formulas used by French President Francois Mitterrand to successfully treat his advanced Prostate Cancer. Based on the scientific research of Mirko Beljanski, PhD, one of the first green molecular biologists Jason & Kristina Walker - farmers, ranchers, Starwalker Farms 7000 acres of Regenerative, Organic, Beef, Pork & Chicken raised in Northern California. Why the Beef, Pork, and Chicken taste better, contains more food value and is better for the environment Brenda Snow - author, Diagnosed the Essential Guide to Navigating the Patient Journey Find the resources you need for a successful outcome find us at: www.HeresToYourHealthWithJoshuaLane.com
Dr. Chuck Link is the Executive Chairman of Syncromune, a company developing a novel immunotherapy approach for solid tumors by delivering the therapy into the tumor and surrounding lymph nodes to stimulate a systemic immune response. Their complex drug has four different components with varying levels of activity that activate the immune system and counteract immune suppression. This in situ immunotherapy technology, SYNC-T, was tested in a phase 1 trial for metastatic castration-resistant prostate cancer, which showed high response rates and a favorable safety profile with low rates of serious side effects and minimal autoimmune toxicity. Chuck explains, "So, SYNC-T is a technology in which you put a needle directly into a tumor that can be done by a urologist in the prostate cancer situation, or by an interventional radiologist. That needle then the tip of it freezes, and does a freeze fracture. Think of a Coke bottle rupturing like in the freezer. And what that does is release the antigens from that patient's own specific tumor. So, it's personalized because the tumor proteins and antigens are used to create a vaccine effect that's released directly from the cancer." "The tumor microenvironment is basically within the tumor itself, and there are immune suppressive mechanisms that the tumor has evolved to protect it from the immune system. I like to think of it as a castle, multiple levels of defense where you have the castle itself, and then you have a castle wall, and then you have a moat, and then an army in front of the wall. So the cancer has multiple immune-suppressive mechanisms that are activated to defeat the immune system, even though cancer has a lot of abnormal, mutated proteins that the immune system should attack and destroy. So what SYNC-T accomplishes is it basically hits solutions for all four of those types of defense simultaneously to make it more difficult for the castle, in this case, the tumor, to protect itself." #Syncromune #Immunotherapy #MetastaticSolidTumors #Cancer #ProstateCancer syncromune.com Download the transcript here
Dr. Chuck Link is the Executive Chairman of Syncromune, a company developing a novel immunotherapy approach for solid tumors by delivering the therapy into the tumor and surrounding lymph nodes to stimulate a systemic immune response. Their complex drug has four different components with varying levels of activity that activate the immune system and counteract immune suppression. This in situ immunotherapy technology, SYNC-T, was tested in a phase 1 trial for metastatic castration-resistant prostate cancer, which showed high response rates and a favorable safety profile with low rates of serious side effects and minimal autoimmune toxicity. Chuck explains, "So, SYNC-T is a technology in which you put a needle directly into a tumor that can be done by a urologist in the prostate cancer situation, or by an interventional radiologist. That needle then the tip of it freezes, and does a freeze fracture. Think of a Coke bottle rupturing like in the freezer. And what that does is release the antigens from that patient's own specific tumor. So, it's personalized because the tumor proteins and antigens are used to create a vaccine effect that's released directly from the cancer." "The tumor microenvironment is basically within the tumor itself, and there are immune suppressive mechanisms that the tumor has evolved to protect it from the immune system. I like to think of it as a castle, multiple levels of defense where you have the castle itself, and then you have a castle wall, and then you have a moat, and then an army in front of the wall. So the cancer has multiple immune-suppressive mechanisms that are activated to defeat the immune system, even though cancer has a lot of abnormal, mutated proteins that the immune system should attack and destroy. So what SYNC-T accomplishes is it basically hits solutions for all four of those types of defense simultaneously to make it more difficult for the castle, in this case, the tumor, to protect itself." #Syncromune #Immunotherapy #MetastaticSolidTumors #Cancer #ProstateCancer syncromune.com Listen to the podcast here
When former president Joe Biden was diagnosed with prostate cancer, Randy Jones was not surprised. He's a professor of nursing at the University of Virginia, and he knows that one in eight American men will eventually get the disease. There are various treatments that may lead to a cure, but it's not always easy to […]
In our latest episode, host Michelle Dawes Birt and special guest Kipper Jones as they dive into their personal healing journeys. From navigating chronic pain to overcoming health challenges, they share inspiring stories and insights that can empower you to prioritize your well-being. Kipper Jones developed his musical skills as a teenager working at Motown, absorbing the nuances of songwriting and production. This early experience laid the foundation for his own successful career as a hitmaker. Special thanks to Kipper Jones for sharing his incredible journey and insights into prioritizing your well-being. Don't let fear hold you back—tune in now and discover how to embrace life more abundantly! Are you subscribed to the podcast? If not, make sure to subscribe so you never miss an episode. Please remember to rate, comment, share, and download your favorite episodes. Connect with Real Chicks Rock! Instagram - https://www.instagram.com/realchicksrock Facebook - https://www.facebook.com/RealChicksRock1 Twitter - https://twitter.com/RealChicksRock1 Website: www.RealChicksRock.com Connect with Kipper Jones: Instagram: https://www.instagram.com/kipperjones #RealChicksRock #RealDiscussions #KipperJones #HealingJourney #HealthAwareness #ChronicPain #HipReplacement #Music #MusicJourney #Atlanta #LosAngeles #Empowerment #Inspiration #Podcast #Singer #Songwriter #Musicians #Creativity #BlackExcellence #MusicMatters #YouTube #YouTuber #YoutubeChannel #YouTubeVideo I DO NOT OWN ANY MUSIC IN THIS VIDEO! [MUSIC & COPYRIGHT PERMISSION WAS GRANTED BY KEVIN HYMAN FOR KEMIT MUZIK, LLC FOR SONG WE STILL RISE (THE LOUNGE LIZARDS BOOTLEG MIX) ] THE MUSIC IS FOR PROMOTIONAL USE ONLY.
In our June episode, Dr. Martin Karpeh from Northwell Health helped us kick off Men's Health Awareness Month, examining the unique challenges men face and sharing simple steps they can take to take charge of their health. In this month's Key Note, Dr. Karpeh talks about his participation in a panel discussion that explored the impact that prostate cancer has on Black men. To view the video, visit The Unspoken Truth: A Dialogue on Prostate Cancer Among Black Men. The Takeaway We want to hear from you! Please complete our survey: 1199SEIUBenefits.org/member-feedback. Drop us a line at our social media channels: Facebook // Instagram // YouTube. Start your health journey by making an appointment with your primary care physician to know your numbers. Get to know your numbers at www.1199SEIUBenefits.org/healthyhearts. Due for a screening? Check out www.1199SEIUBenefits.org/get-screened Find healthy recipes and meal-prep tips at www.1199SEIUBenefits.org/food-as-medicine. Visit the Healthy Living Resource Center for wellness tips, information and resources; www.1199SEIUBenefits.org/healthyliving. Get inspired by fellow members through our Members' Voices series: www.1199SEIUBenefits.org/healthyliving/membervoices. Stop by our Benefits Channel to join webinars on building healthy meals, managing stress and more: www.1199SEIUBenefits.org/videos. Visit our YouTube channel to view a wide collection of healthy living videos: www.youtube.com/@1199SEIUBenefitFunds/playlists. Sample our wellness classes to exercise body and mind: www.1199SEIUBenefits.org/wellnessevents. Martin Karpeh, MD, is the director of surgical oncology at the Northwell Health Cancer Institute for Northwell facilities across eastern Long Island. He is based at Huntington Hospital, where he is chair of surgery. Dr. Karpeh specializes in gastrointestinal tumors, including stomach and esophageal cancer, and cancers of the gastroesophageal junction. In the 1990s, he helped introduce minimally invasive laparoscopic staging techniques that now guide treatment decisions, helping doctors determine whether patients receive chemotherapy before surgery for gastroesophageal junction cancer. He also treats soft tissue sarcomas and skin cancers, including melanoma, squamous cell carcinoma and Merkel cell carcinoma. Dr. Karpeh received his medical degree from the Pennsylvania State University Medical Colleges. He went on to complete his General Surgical Training at the University of Pennsylvania and later a Surgical Oncology Fellowship at Memorial Sloan Kettering Cancer Center, where he spent more than a decade as an attending. He then spent 20 years leading surgical oncology programs at Stony Brook University Medical Center, Mount Sinai Beth Israel Medical Center and Hackensack Meridian Health. For decades, Dr. Karpeh has worked in clinical trial development and frequently refers patients to national and international clinical studies. He is involved in translational research at Cold Spring Harbor Laboratory to identify treatment targets in stomach and esophageal cancers, and has published more than 100 journal articles on stomach and gastroesophageal junction cancer. A member of the International Gastric Cancer Association, the Society of Surgical Oncology and the American Surgical Association, Dr. Karpeh is also the former president of the New York Surgical Society, New York Cancer Society and the Society of Black Academic Surgeons. Additionally, he has been named a Castle Connelly Top Doctor and New York Magazine Top Doctor over many years.
Last month, former President Joe Biden announced that he had been diagnosed with an aggressive form of prostate cancer. The news sparked a larger conversation about what exactly the best practices are to screen for prostate cancer. Turns out, it's more complicated than it might seem. Host Ira Flatow is joined by oncologist Matthew Cooperberg and statistician Andrew Vickers, who studies prostate cancer screening, to help unpack those complexities.Transcripts for each episode are available within 1-3 days at sciencefriday.com. Subscribe to this podcast. Plus, to stay updated on all things science, sign up for Science Friday's newsletters.
In this powerful episode of the Dr. Geo Prostate Podcast, Dr. Geo sits down with Dr. Preston Sprenkle, leading urologic oncologist at Yale School of Medicine, to explore the emerging role of focal therapy in prostate cancer care. A pioneer in MRI-ultrasound fusion biopsy using the Artemis Device, Dr. Sprenkle shares how focal treatments can offer cancer control while preserving quality of life.Whether you're on active surveillance or facing a Gleason 7 or 8 diagnosis, this episode helps you better understand:When focal therapy is appropriate—and when it's notKey differences between cryoablation, IRE (NanoKnife), and Tulsa Pro How patient goals (erectile function, continence, cancer control) shape treatmentWhat recent research shows about focal therapy success ratesHow to approach higher-risk prostate cancer (Gleason 8–10) with focal therapyWhat to know about PSMA PET scans, genomic tests, and repeat biopsiesThe real risks of skipping follow-up on active surveillanceYou'll also hear candid reflections on the evolution of holistic and integrative urology, and why building trust with your urologist matters more than ever.
Welcome to this week's episode of our podcast, where we delve into an important and often discussed topic in men's health—prostate cancer. Today, we'll explore the latest insights into how prostate cancer is diagnosed and treated, providing valuable information for both patients and healthcare providers. A key focus will be on the role of PSA testing, its benefits, limitations, and how it fits into the broader screening and diagnostic process. Joining us as our expert guest is Dr. Brian Miles, a renowned specialist in urology and prostate health. With his expertise, we aim to shed light on current advancements, best practices, and emerging trends in prostate cancer management. Whether you've just been diagnosed, are due for screening, or simply want to stay informed, this episode offers essential knowledge to help you navigate this important health topic. Stay tuned!Where to find Dr. Joe Galati and his team:Dr. Galati's newsletter sign-upMedical Practice: Liver Specialists of TexasDr. Galati's Book Site: Eating Yourself SickFacebook: Dr. Joe GalatiDr. Galati's YouTube ChannelPlease send feedback and suggestion. You can message me here. Hosted on Acast. See acast.com/privacy for more information.
Dr. Shiksha Gallow currently serves as the Medical Director of the Holistic Integrative Healing Institute and is notably the first and only South African to sit on the Board of Directors of the Society of Cannabis Clinicians. Dr. Gallow's passion lies in leveraging her medical and scientific expertise to develop Active Pharmaceutical Ingredients (APIs) from cannabis and other plant species to treat various conditions. She has achieved significant success in treating patients with autoimmune diseases and cancer, and she strongly advocates for patient access to safe and effective medicines that improve quality of life. At CannMed 25 she will present “Comprehensive Evaluation of the ‘Impact of Cannabinoids' on Prostate Cancer: Integrating PSA, PET/CT Scans and Patient-Related Outcomes” During our conversation we discuss The variety of treatment options for prostate cancer and the role of cannabinoids may play Results from an empirical study that evaluated how cannabinoid treamtment impacts PSA levels PET/CT scans and patient reported outcomes How patients were selected and grouped for the study Future research opportunities and more Thanks to This Episode's Sponsor: PRICH Biotech PRICH Biotech, Corp. is a vertically integrated company dedicated to the cultivation, manufacture and dispensing of medicinal Cannabis in Puerto Rico. With over 500,000 square feet of STATE OF THE ART facilities, Prich uses the highest standards of agricultural and manufacturing practices to Guarantee the highest standard of medicinal cannabis. Their mission is to offer a natural and unique experience through medicinal cannabis that raises the patient's well-being and quality of life. Learn more at prichbiotech.com. Additional Resources Dr. Gallow on Linkedin Holistic Healing Dr Gallow (Facebook) CannMed Video Archives
According to the American Cancer Society, approximately one in eight men will be diagnosed with a prostate condition during their lifetime. Focused ultrasound offers a noninvasive, radiation-free treatment option for prostate conditions and has been approved in more than 50 countries, including the United States. In this episode of Curing with Sound, we explore focused ultrasound for prostate cancer through the lens of a patient and a patient advocate. Bob Palmer, who underwent the TULSA-PRO procedure—a minimally invasive, incision-free focused ultrasound treatment—discusses his decision-making process and treatment experience. He is joined by Eve Satterthwaite, a registered nurse and patient educator at Profound Medical. She provides an overview of what patients can expect from the procedure and her role in guiding them through treatment. Bob shares how Eve helped him evaluate treatment options after his prostate cancer diagnosis and what led him to choose focused ultrasound, particularly in light of potential side effects associated with surgery and radiation. Eve explains how she helps patients understand their options, outlines the clinical benefits of the TULSA procedure, and addresses common patient concerns. Discussion highlights: Modern Prostate Treatment Options – An overview of the TULSA-PRO procedure, an FDA-approved focused ultrasound treatment that offers an incision-free alternative to traditional prostate cancer treatments, with minimal downtime and reduced risk of side effects affecting quality of life. Informed Choices Through Education – Insights into how clear, comprehensive information about available treatments can help patients make confident, well-informed decisions. All patient stories featured on the Curing with Sound podcast are personal accounts of an individual's experience with focused ultrasound treatment. Please be aware that each patient's situation is unique, and outcomes may vary. The information provided in this story should not be considered as medical advice or a guarantee of specific results. It is important to consult with a qualified healthcare provider to discuss your condition and determine the best treatment options for you. The Focused Ultrasound Foundation does not endorse any specific treatment or medical procedure and encourages all patients to seek professional medical guidance tailored to their individual needs. Visit TULSAprocedure.com for more information EPISODE TRANSCRIPT ---------------------------- QUESTIONS? Email podcast@fusfoundation.org if you have a question or comment about the show, or if you would you like to connect about future guest appearances. Email info@fusfoundation.org if you have questions about focused ultrasound or the Foundation. FUSF SOCIAL MEDIA LinkedIn X Facebook Instagram TikTok YouTube FUSF WEBSITE https://www.fusfoundation.org SIGN UP FOR OUR FREE NEWSLETTER https://www.fusfoundation.org/newsletter-signup/ READ THE LATEST NEWSLETTER https://www.fusfoundation.org/the-foundation/news-media/newsletter/ DOWNLOAD "THE TUMOR" BY JOHN GRISHAM (FREE E-BOOK) https://www.fusfoundation.org/read-the-tumor-by-john-grisham/
Did you know that prostate cancer is the second most common cancer in men worldwide? The good news? When detected early, prostate cancer is highly treatable.On this episode of the Healthier You podcast, Dr. Ashlee Williams speaks with Dr. Dock Winston, a board-certified urologist at Kaiser Permanente, about prostate cancer: the risks, symptoms, screening, and treatment options that every man should know.
In this episode of The Common Sense MD, Dr. Tom Rogers dives deep into one of the most debated topics in men's health: PSA screening for prostate cancer. June is Men's Health Month, and Dr. Rogers uses this timely opportunity to address widespread confusion and anxiety surrounding PSA (prostate-specific antigen) testing.Drawing from recent headlines—including the news about Joe Biden's missed prostate cancer diagnosis—Dr. Rogers explores why prostate cancer screening is so controversial, the shortcomings of current medical recommendations, and the risks of both over- and under-testing. He explains who should get screened and when, discusses the nuances of PSA interpretation, and highlights the importance of being your own health advocate.Listeners will also learn practical tips for getting accurate PSA test results, the value of baseline screenings, the role of digital rectal exams, and the importance of monitoring PSA velocity and free PSA percentage. Dr. Rogers demystifies what PSA numbers mean, touches on advanced testing options, and reminds men not to panic if their PSA is elevated—instead, emphasizing thoughtful follow-up and individualized care.Whether you're confused about screening guidelines, worried about your own results, or simply want to be proactive about your health, this episode provides clear, common-sense advice rooted in real-world medical experience. Tune in to get the facts on prostate health, advocate for yourself, and make the most informed decisions possible.What did you think of this episode of the podcast? Let us know by leaving a review!Connect with Performance Medicine!Check out our new online vitamin store:https://performancemedicine.net/shop/Sign up for our weekly newsletter: https://performancemedicine.net/doctors-note-sign-up/Facebook: @PMedicineInstagram: @PerformancemedicineTNYouTube: Performance Medicine
52:10- Lt. Col. Chuck DeVore (Ret.), Chief National Initiatives Officer at the Texas Public Policy Foundation who served as a Republican member of the California State Assembly from 2004 to 2010 Topic: "Trump moves fast to save LA from a 1992 repeat" (Fox News op ed) 1:02:25- Dr. Gil Lederman, Expert in Prostate Cancer and the host of "Radiosurgery New York with Dr. Gil Lederman" on AM 970 The Answer Topic: Biden's prostate cancer prognosis 1:12:30- Dr. Marc Siegel, physician, Professor of Medicine at the NYU Langone Medical Center, author, and contributor to Fox News Topic: "Grandma and Grandpa are turning golden years into a high time and it’s not safe" (Fox News op ed) 1:25:19- John Solomon, award-winning investigative journalist, founder of "Just The News," and the host of “Just the News, No Noise” on the Real America’s Voice network Topic: Miguel Uribe assassination attempt, other news of the day 1:32:31- Nicole Parker, Special Agent with the FBI from 2010 through October 2022 and a Fox News contributor Topic: FBI involvement in the Los Angeles protests 1:49:06- Rich Lowry, Editor of the National Review and the author of "The Case for Nationalism" Topic: "Biden WH flack Karine Jean-Pierre’s latest ruse just moves her from one ‘grift’ to another" (New York Post op ed) 2:01:56- Thomas Homan, Border Czar for the Trump administration Topic: Los Angeles protestsSee omnystudio.com/listener for privacy information.
Today's programme is all about prostate cancer; exploring what the disease is, who gets it, and how it can be treated. We'll explore the game-changing test from a Cambridge based firm, and question whether sometimes the best approach is to leave the cancer alone... Like this podcast? Please help us by supporting the Naked Scientists
Gary comments on several recent news items, hoping to bring a bit of sanity (and biblical worldview) to the cultural craziness. The Catholic Church, SPLC, Charlie Kirk, transgenderism, and track and field all get a bit of analysis from Gary. He even closes the episode with a bit of health advice. It has something for everyone!
One in eight men will be diagnosed with prostate cancer, and President Biden's recent diagnosis has many people asking: Am I at risk? Should I get screened? Dr. Sanjay Gupta breaks down what to know about PSA tests, family history, screening age, and how your diet might factor in. Learn more about your ad choices. Visit podcastchoices.com/adchoices
The news last week of former President Joe Biden's advanced prostate cancer has more people thinking and talking about the condition.About 1 in 8 men in the U.S. are diagnosed with prostate cancer at some point in their lives. It's the most-diagnosed cancer in men and the second-leading cause of cancer-related death in American men after lung cancer. That's according to the American Cancer Society.In this installment of our series, "In Good Health," we talk about how to detect and treat prostate cancer. Then, we switch gears to talk about the Food and Drug Administration's plans to potentially restrict access to the COVID-19 vaccine.Want to support 1A? Give to your local public radio station and subscribe to this podcast. Have questions? Connect with us. Listen to 1A sponsor-free by signing up for 1A+ at plus.npr.org/the1a.Learn more about sponsor message choices: podcastchoices.com/adchoicesNPR Privacy Policy
On today's episode, Andy & DJ discuss Biden breaking his silence after revealing he's battling with aggressive prostate cancer, James Comey's weird social media approach landing him in hot water, and the video of the Indian version of the Titanic.